D4 Bioventures Advises Lucid Health Consulting on its Sale to IQVIA

D4 Bioventures acted as exclusive corporate advisor to Lucid Health Consulting on its sale to IQVIA (NYSE: IQV) — a strategic outcome that combines one of Australia’s leading market access consultancies with the world’s largest healthcare data and clinical research platform.

Sydney, Australia  ·  April 2026

D4 Bioventures (“D4”), a specialist corporate advisory and venture studio group focused on life sciences and healthcare, is delighted to announce that it acted as exclusive advisor to Lucid Health Consulting (“Lucid”) on its sale to IQVIA (NYSE: IQV).

Lucid Health Consulting is a premier Australian consultancy specialising in market access, pricing strategy, health economics, and commercialisation support. Lucid has built a market-leading reputation for rigorous analysis and trusted partnerships across the Australian healthcare ecosystem.

IQVIA, headquartered in Durham, North Carolina, is one of the world’s largest healthcare data science and clinical research organisations. Operating in more than 100 countries with a market cap of approximately US$30bn, IQVIA provides integrated solutions spanning real‑world evidence, clinical development, and technology‑enabled insights.

The integration of Lucid into IQVIA strengthens the combined organisation’s capabilities across Australia and New Zealand, particularly in pricing, market access, and real‑world evidence generation.

A Strategic Outcome

Michael Aristides, Director of Lucid Health Consulting, said:

“This is a significant milestone for Lucid, and we are proud of the team we have built. D4 Bioventures was instrumental in guiding us through this process. Their strategic insight, sector expertise, and commitment were exceptional.”

— Michael Aristides, Director, Lucid Health Consulting

Jeremy Waine, Principal at D4 Bioventures, added:

“Lucid is one of Australia’s most respected market access consultancies, and it has been a privilege to support the founders. The logic behind the IQVIA integration is clear — combining Lucid’s deep local expertise with IQVIA’s global scale and data assets.”

— Jeremy Waine, Principal, D4 Bioventures

D4 Bioventures has deep knowledge of the healthcare, life sciences, and specialist consulting sectors, and welcomes confidential discussions with founders, boards, and investors considering strategic options, capital partnerships, or M&A pathways.

About D4 Bioventures

D4 Bioventures is a venture studio and boutique corporate advisory firm dedicated to transforming life science and healthcare innovations into well-funded, market-ready enterprises. We specialise in venture building for universities, medical research institutes and early-stage companies, and in capital raising, corporate structuring and M&A for life science and health sector companies.

Media & Confidential Enquiries

Jeremy Waine

Principal, D4 Bioventures

Email:  jeremy@d4bioventures.com.au

Phone:  0418 529 999

Website:  www.d4bioventures.com.au